This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Future Medicine Co., Ltd.. Active years: 2022-2024.
Company Filing History:
Years Active: 2022-2024
Title: Innovations of Chong-Woo Park in Pharmaceutical Composition
Introduction
Chong-Woo Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions aimed at treating various diseases. With a total of 2 patents, his work focuses on innovative solutions for retinal and diabetic conditions.
Latest Patents
Chong-Woo Park's latest patents include a pharmaceutical composition comprising an adenosine derivative for the prevention and treatment of retinal disease or optic nerve disease. This invention relates to a pharmaceutical composition, an oral administration agent, and an eye drop that effectively prevent or treat retinal diseases or optic nerve diseases. The active ingredient is represented by a specific chemical formula or a pharmaceutically acceptable salt thereof. Another significant patent is a pharmaceutical composition for preventing and treating diabetic nephropathy, which also includes an adenosine derivative compound as an active ingredient.
Career Highlights
Chong-Woo Park is currently associated with Future Medicine Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments that address critical health issues.
Collaborations
Chong-Woo Park collaborates with talented individuals such as Mi Ra Yu and Bo Mi Park, contributing to a dynamic research environment that fosters innovation.
Conclusion
Chong-Woo Park's contributions to pharmaceutical compositions demonstrate his dedication to advancing medical science. His innovative patents reflect a commitment to improving health outcomes for patients suffering from retinal and diabetic conditions.